Sinovac’s 10 billion yuan plans include new facility, global HQ in Singapore: Lianhe Zaobao
CHINESE vaccine maker Sinovac Biotech is investing 10 billion yuan (S$2 billion) in a development plan which includes opening a research facility and its international headquarters in Singapore, Lianhe Zaobao reported on Wednesday (Jun 15).
The research facility will develop vaccines for Covid-19 and severe hand, foot and mouth disease, and may be operational as early as within the next few months, said Helen Yang, Sinovac’s Hong Kong general manager and chief business officer.
She shared Sinovac’s plans in an interview with Zaobao last week, while in Singapore to discuss cooperation with local organisations. The 10 billion yuan figure includes opening a research facility in Singapore or collaborating with local research institutes to study new pathogens – though it is unclear exactly how much will be invested in Singapore itself.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
Chinese firms are investing abroad at fastest pace in eight years
Sri Lanka’s economy expected to grow 3% in 2024, central bank says
Yellen says US can bring inflation down without hurting jobs
US dollar briefly falls versus yen after GDP data
US weekly jobless claims unexpectedly fall
US economic growth slows more than expected in Q1